Strong US dollar hurts Swiss pharmaceutical company Novartis with 32-per cent drop in Q2 profit + MORE Jul 21st

There are more investment options in Canada than you can shake a stick at! Stay on top of the best returns right here.
Latest News

How are you taxed when you sell a small business? + MORE Apr 11th

I recently sold my company last year for $160,000 and purchased it for $90,000 in 1997. Can you please help me with the tax on this? I have called CRA many times and no one knows this simple process.—Peter The types of taxes you owe when selling a small business Sorry you have been having tr.... More »

South Korea moves to minimize disruption from shipper’s woes + MORE Sep 5th

SEOUL, South Korea – South Korea’s financial regulator says financially troubled Hanjin Shipping Co. is seeking stay orders in dozens of countries to help minimize disruptions caused by its slide into bankruptcy proceedings. The Financial Services Commission said Monday that Hanjin, the .... More »
 TSE

Capital gains tax in Canada, explained + MORE Jan 31st

Capital gains tax highlights Investors can sigh relief for the 2024 tax year. Despite the capital gains inclusion rate being changed as of June 25, 2024, it has since been delayed until 2026 by the Department of Finance Canada. Here’s what is proposed. For individuals, the inclusion rate is eithe.... More »

Planning for retirement with little or no savings to draw on Jul 9th

Despite their best intentions some Canadians, facing a variety of financial challenges throughout their working lives, may not be able to save much towards retirement. Yet it’s difficult to know how to manage in those circumstances, as so much of the financial planning advice that’s shared widel.... More »

Prince Harry, Meghan thrown cruel insult as King takes strict action - The News International Nov 3rd

Prince Harry, Meghan thrown cruel insult as King takes strict action  The News InternationalKing ‘cuts financial ties to disgraced Prince Andrew after refusal to move out of home’  The IndependentPrincess Eugenie and Princess Beatrice dealt inheritance blow over Royal Lodge '.... More »
TOKYO – Toshiba’s chief executive resigned Tuesday to take responsibility for doctored books that inflated profits at the Japanese technology manufacturer by 152 billion yen ($1.2 billion) over several years.
Toshiba Corp. acknowledged a systematic coverup, which began in 2008. Various parts of the Japanese company’s sprawling business including computer chips and personal computers were struggling financially, but top managers set unrealistic earnings targets under the banner of “challenge,” and subordinates faked results.
On top of its struggles in electronics, Tokyo-based Toshiba’s prospects in nuclear power, one of its core businesses, were shaken after the 2011 Fukushima disaster set off public fears about reactor safety, making new nuclear plants unlikely in Japan. All 48 of the nation’s working reactors are now offline.
Bowing deeply before flashing cameras at a news conference, CEO Hisao Tanaka kept his head lowered for nearly half a minute in a gesture meant to convey deep shame and contrition…

Continue Reading On canadianbusiness.com »

The best of the web on money, markets and all things financial, as chosen daily by Globe and Mail personal finance columnist Rob Carrick

Continue Reading On theglobeandmail.com »

Beware the hype of the next big deal

– theglobeandmail.com

The financial crisis was supposed to teach us about falling for resource boom hype, yet CEOs make the same mistakes over and over again

Continue Reading On theglobeandmail.com »

BERLIN – Swiss-based pharmaceutical giant Novartis’ second-quarter net income dropped 32 per cent over the same quarter last year, brought down primarily by poor performance from associated companies and negative effects of a strong U.S. dollar, the company said Tuesday
Net income was $1.856 billion, down from $2.723 billion in the same quarter in 2014. Net sales were down 5 per cent to $12.694 billion and earnings per share from continuing operations dropped to $0.77 from $1.11 last year.
Nevertheless, CEO Joseph Jimenez said the company had a strong quarter for innovation with the U.S. approval and launch of two new drug products — heart failure drug Entresto and multiple sclerosis therapy drug Glatopa — and confirmed its full-year guidance.
Group sales are expected to grow by mid-single digits and operating income is expected to grow ahead of sales at a high-single-digit rate, Novartis has said.
“We are confident we will deliver on our priorities for the year,” Jimenez said…

Continue Reading On canadianbusiness.com »

Drug makers lead European stocks slightly lower; crude oil continues to skid on oversupply concerns

Continue Reading On theglobeandmail.com »

Share

PinIt
Compare insurance quotes through Kanetix.ca - save time and money!